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Abstract: Purpose: Bevacizumab as an adjunct to chemotherapy improves survival for some patients with meta-
static colorectal cancer. Immunohistochemical staining of samples from the registration ECOG E3200 trial of beva-
cizumab with FOLFOX demonstrated that only patients with carcinomas expressing low levels of VEGF-A165b, an anti-
angiogenic splice variant of the Vascular Endothelial Growth Factor family of proteins, benefited from bevacizumab 
treatment. To identify a more useful biomarker of response we tested the hypothesis that circulating VEGF-A165b 
levels correlate with immunohistochemical staining. Experimental Design: 17 patients with biopsy proven colorectal 
adenocarcinoma had pre-operative blood samples drawn. They underwent resection and had post-resection blood 
drawn. The plasma was analysed for levels of VEGF-Axxxb using enzyme-linked immunosorbent assay (ELISA) and 
the tumour blocks stained for VEGF-Axxxb and pan-VEGF-A. The normalised ratio of VEGF-Axxxb expression to that of 
panVEGF-A expression scored by IHC was calculated and correlated with plasma VEGF-A165b levels. Results: Plasma 
levels of VEGF-Axxxb significantly correlated with the VEGF-Axxxb:panVEGF-A ratio (r=0.594, P<0.02) in colorectal can-
cers. Median plasma VEGF-Axxxb levels were 151 pg/ml. The mean (1.5±0.17) and median, IQR (1.8, 1-2) IHC scores 
of the patients with greater than median plasma VEGF-Axxxb were significantly greater than those with less than 
median plasma VEGF-Axxxb levels (mean ± SEM=0.85±10.12, median, IQR=1, 0.54-1). Conclusion: These results 
suggest that plasma VEGF-Axxxb levels could be an effective biomarker of response to Bevacizumab. These results 
indicate that a prospective trial is warranted to explore the use of plasma VEGF-Axxxb levels to stratify patients for 
colorectal cancer treatment by bevacizumab.
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Introduction
Tumour angiogenesis is one of the hallmarks of 
cancer [1], and is mediated by a variety of 
growth factors, the most widely studied of 
which is vascular endothelial growth factor 
(VEGF-A). High plasma levels of total VEGF-A 
may be observed in more advanced colorectal 
cancer [2] and the anti-VEGF-A monoclonal 
antibody Bevacizumab (Avastin®) increases 
median survival by a matter of weeks when 
given with chemotherapy in metastatic colorec-
tal cancer [3, 4]. However, the response rate of 
patients to Bevacizumab is only around 10%, 
with responses not predicted by total VEGF-A 
levels [5]. VEGF-A is a multi-exon gene encod-
ing multiple isoforms, identified by their amino 
acid number (e.g. VEGF-A165, VEGF-A121 etc.). 
Alternative splicing of exon 8 results in 2 fami-
lies of proteins [6]. Depending on the resultant 
protein translated, the physiological outcome is 
either that of promotion or inhibition of 
microvessel formation. Proximal splice site 
(PSS) usage generates a short open reading 
frame (ORF) of 6 amino acids common to the 
pro-angiogenic VEGF-Axxx isoforms. Alternative 
distal splice site (DSS) selection in exon 8 
results in a different 6 amino acid ORF, result-
ing in proteins of the same length as the pro-
angiogenic isoforms, but with a different termi-
nal sequence. These VEGF-Axxxb isoforms are 
anti-angiogenic in physiological systems [7], in 
experimental VEGF-A-driven angiogenesis [8], 
and in pathologic angiogenesis driven by 
VEGF-A [9], including in tumours [10-13]. 
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The anti-angiogenic VEGF-Axxxb isoforms are 
the predominant isoforms in normal human 
colon among other tissues [13]. Furthermore 
VEGF-Axxxb isoforms are present in colonic ade-
noma and appear to be down regulated in colon 
cancer, but with substantial inter-patient vari-
ability [13]. The ratio of VEGF-Axxx:VEGF-Axxxb 
may have implications for anti-angiogenic ther-
apy with Bevacizumab, as recently demonstrat-
ed in a study of patients who had been treated 
with chemotherapy with or without Beva- 
cizumab. This study showed immunohisto-
chemical (IHC) staining of tumours for VEGF-
Axxxb predicted disease free survival in patients 
being treated with Bevacizumab and oxaliplatin 
based chemotherapy [14]. This was using a 
subjective (although blinded) scoring system 
and required normal mucosa and tumour to be 
stained with both VEGF-Axxxb and pan-VEGF 
antibodies. A more objective, non-invasive 
measure of VEGF-Axxxb levels, for instance cir-
culating VEGF-Axxxb levels, would provide a 
cleaner and easier assessment criteria for bev-
acizumab treatment. 
We therefore set out to test the hypothesis that 
plasma VEGF-Axxxb levels measured by ELISA 
can be used to predict the staining outcome. 
Materials and methods
Plasma and tissues was obtained from 18 
patients diagnosed with colorectal adenocarci-
noma at the Bristol Royal Infirmary between 
May 2013 and December 2013. Ethics approv-
al for the study was obtained from the North 
Somerset and South Bristol Research Ethics 
Committee (07/H0102/45) and protocols con-
formed to the tenets of the Declaration of 
Helsinki, as revised in 2008. A venous blood 
sample was obtained from each participant 
after informed written consent.
Preparation
During pre-operative assessment, 1 week 
before surgery, blood was drawn and sent up to 
the laboratory in EDTA-treated vacutainers, 
within 60 minutes from being drawn (identified 
for rapid processing using special labels). Post-
operative plasma samples were collected by 
the same protocol 24-48 hours post-procedure. 
Pre-and post-operative blood samples were 
centrifuged for ten minutes at 3200 rpm and 
plasma was collected and frozen at -80°C.
The colorectal carcinoma specimens were for-
malin-fixed and paraffin embedded. They were 
cut at 5 µm and stained using pro-angiogenic 
and anti-angiogenic antibodies using an auto-
mated immunohistochemistry process (Leica 
Bond III, Leica Biosystems).
Immunohistochemistry
All isoforms of VEGF-A, termed VEGF-Atotal or 
Pan-VEGF-A were examined by immunohisto-
chemistry using a commercially available anti-
VEGF-A antibody (A20, Santa Cruz, rabbit poly-
clonal) at 2 µg/ml in an automated machine 
(Leica Bond III, Leica Biosystems) in 1:100 
EDTA buffer. This detects isoforms generated 
by both proximal splice site and distal splice 
site by identifying the C-terminus. One patient 
sample was lost during tissue processing.
VEGF-Axxxb expression was examined by immu-
nohistochemistry using a mouse monoclonal 
IgG1 antibody raised to the terminal nine amino 
acids of the VEGF-A165b sequence. It was affini-
ty purified against the antigen from conditioned 
media of hybridoma cells (Abcam MRVL56/1). 
It has previously been shown to have specificity 
for the VEGF-A165b isoform over the VEGF-A165 
isoforms and does not detect VEGF-A165, or 
VEGF-A121, recombinant protein [15, 16]. This 
antibody has a VEGF-A165b association con-
stant of 3x104 (mol/L)-1s-1 and dissociation con-
stant of 0.011s-1 but no affinity with VEGF-A165 
[10]. It also detects other VEGF-Axxxb isoforms 
such as VEGF-A121b, VEGF-A145b, and VEGF-
A189b in human tissues [16]. It was used at 37 
µg/ml in 1:35 EDTA buffer. Negative controls 
received a matched concentration of IgG of the 
primary animal (mouse or rabbit).
Slides were independently assessed and stain-
ing intensity scored (1-4). All sections were 
examined, conducted by 3 different assessors, 
blinded to treatment (JB, GSF and DOB). The 
intensity of DAB staining was graded from 1-4 
in the normal mucosal tissue and the most 
poorly differentiated tumour for each section. 
Stroma was not scored. Tissue staining was 
scored as follows:
SCORE DEGREE OF STAINING
1 Weak staining
2 Moderate staining
3 Strong staining
4 Intense staining
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Figure 1. Immunohistochemical staining for VEGF-Axxxb, pan-
VEGF and control (mouse IgG) from normal mucosa and from 
colorectal cancer samples. Staining intensity was scored from 
1-4. Scale bar = 100 µm.
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Normal colonic mucosa adjacent to the tumour 
acted as a positive control and was used to 
determine the relative intensity of the VEGF-A 
isoforms between adenocarcinoma and normal 
mucosa. The ratio of the 2 scores was then cal-
culated (VEGF-Axxxbnormal/tumour:panVEGF-Anormal/
tumour).
ELISA
Plasma samples were assessed for expression 
of both VEGF-Axxxb and panVEGF-A, a measure 
of both VEGF-Axxx and VEGF-Axxxb isoforms, 
using Enzyme-Linked Immunosorbent Assay 
(ELISA). 
An Immunoassay 96 well plate (Thermo Life 
Sciences) was coated with a mouse anti-VEGF-
A165b monoclonal antibody (Clone 56/1, 
MAB3045, R&D Systems) at a concentration of 
10 µg/ml, covered with parafilm and protected 
from light, then left shaking at room tempera-
ture (RT) overnight (~16 hours). 
panVEGF-A capture was mouse anti-VEGF-A 
monoclonal antibody at 2 µg/ml (MAB293, 
R&D Systems). The plate was then washed 3 
times with 0.05% Tween/PBS (200 µl/well), 
then blocked with 1% BSA/PBS, at 200 µl/well, 
and left for 2 hours at RT. Plates were washed, 
and frozen plasma was thawed and added to 
each well at 100 µl/well.
Recombinant human VEGF-A165b (P/N#842338, 
R&D) or recombinant human VEGF-A (P/N# 
840164, R&D) were used as a control, starting 
at a concentration of 4 ng/ml, at serial dilutions 
to generate a standard curve. Plates were 
washed and biotinylated goat polyclonal anti-
VEGF-A (BAF293, R&D) was added at a concen-
tration of 50 ng/ml, 100 µl/well and incubated 
at RT for 2 hours. 
Plates were washed and HRP-streptavidin 
(P/N#890803, R&D) was diluted 1:200 and 
added at 100 µl/well. This was left at RT for 20 
minutes without shaking and protected from 
light. 
Figure 2. VEGF-Axxxb levels measured in 
plasma. A. Frequency distribution of sam-
ple values. B. VEGF-Axxxb levels before 
and after surgery. BDL= below detection 
limit. C. Correlation of VEGF-Axxxb levels 
before and after treatment. R=0.815, 
P<0.001.
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Following a final wash, HRP substrate (A:B=1:1, 
DY999, R&D) was added in at 100 µl/well and 
incubated at RT in foil for 10-25 minutes. 
Addition of 1M H2SO4 (50 µl/well) was used to 
halt the reaction. 
The plate was read at 450 nm using the plate 
photo spectrometer, with secondary corrective 
reading of the plate at 540 nm or 620 nm to 
adjust for plate optical effect.
Statistics
Statistical analysis was performed using 
Prism6. A probability of <0.05 was considered 
significant. Spearman correlation coefficient 
was used to determine relationships. Diffe- 
rences were assessed using mann whitney U 
test (unpaired) or Wilcoxon paired test.
Results
Immunohistochemical staining
All 17 sections had both normal mucosa and 
tumour tissue. Figure 1 shows examples of 
both normal and tumour tissue stained with 
VEGF-Axxxb and pan VEGF staining, with exam-
ples of different scoring. VEGF-Axxxb was nega-
tively correlated with panVEGF staining (r=-
0.21, P=0.017) but not correlated with AJCC 
score (P=0.1). 
ELISA
VEGF-Axxxb was detected above the ELISA 
detection limit (15 pg.ml-1) in 13/18 patients. 
Median plasma VEGF-Axxxb was 151.1 pg.ml
-1, 
(range, 0-1944), and the distribution of VEGF 
plasma levels was skewed, with a mean of 
527±167 pg/ml (Figure 2A). This is consistent 
with previously published values [13]. There 
was no significant difference between the 
VEGF-Axxxb levels before and after (median 
170.9, range 1-2198 pg.ml-1) surgery (Figure 
2B), although they were highly correlated 
(r=0.815, P<0.001, Figure 2C).
The prognostic index calculated from the ECOG 
data was based on an a priori hypothesis that 
the ratio of the intensity of VEGF-Axxxbnormal/tumour 
to the panVEGFnormal/tumour predicted response to 
bevacizumab. To determine whether this could 
be estimated based on plasma VEGF-Axxxb 
levels, we plotted the VEGF-Axxxbnormal/
tumour:panVEGFnormal/tumour ratio against the plas-
ma VEGF-Axxxb before surgery. There was a sig-
nificant correlation (Figure 3A). The mean 
VEGF-Axxxbnormal/tumour:panVEGFnormal/tumour ratio of 
tumours from patients with a greater than 
median plasma VEGF-Axxxb was significantly 
greater than those with a lower than median 
VEGF-Axxxb plasma concentration (Figure 3B).
Discussion
The use of bevacizumab in treating metastatic 
and other colorectal cancer has raised consid-
erable controversy and discussion. It is clear 
from a number of phase III clinical trials that the 
use of intravenous bevacizumab in combina-
tion with chemotherapy can provide an increase 
in both progression free and overall survival 
ranging from a few weeks to a couple of months. 
It is also clear that only a small subset of 
Figure 3. Predictive staining intensity ratio correlates with plasma VEGF-Axxxb level. A. Correlation of ratio of score of 
VEGF-Axxxb: panVEGF with plasma VEGF-Axxxb level. r=0.594, P<0.02. B. The VEGF-Axxxb: panVEGF ratio was lower in 
patients with less than median plasma VEGF-Axxxb.
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patients can benefit from this treatment, and 
the search for a biomarker has been intense 
and largely fruitless. A few molecular markers 
have been identified by high throughput screen-
ing, but these tend not to have been validated 
in larger studies.
The identification of VEGF-Axxxb levels as a bio-
marker was the first hypothesis driven, target 
mediated clue that tumours may have a molec-
ular phenotype that could help targeting of bev-
acizumab therapy. That study used the tissue 
samples from the primary, independent regis-
tration trial of bevacizumab to show that the 
ratio of VEGF-Axxxb to pan VEGF could be used 
to predict benefit of bevacizumab. In patients 
with a higher than average ratio of VEGF-Axxxb 
to panVEGF there was no benefit in progression 
free survival, whereas in those with less than 
median showed a doubling of progression free 
survival. However although that clinical trial 
recruited over 1000 patients, samples for 
immunohistochemistry were only available for 
287 patients. Of these, one third had been 
entered into a bevacizumab only arm that was 
stopped early due to poor outcomes. Thus only 
179 samples were available for staining,and of 
these only 97 provided staining for both pan 
and VEGF-Axxxb in both normal and tumour tis-
sues. Staining was then assessed by observers 
and scored on a basis compared with normal 
tissue as an internal control. This proces is sub-
jective and difficult to standardise. We there-
fore sought to determine whether a circulating 
marker of VEGF-Axxxb would correlate with the 
ratio, and could be used as potential marker for 
bevacizumab responsiveness.
The results shown here indicate that plasma 
VEGF-Axxxb levels correlate with tissue VEGF-
Axxxb levels. This suggests that circulating 
VEGF-Axxxb levels could be used to determine 
responsiveness to bevacizumab. To do so con-
clusively would require a prospective study of 
plasma VEGF-Axxxb levels in patients treated 
with and without bevacizumab. This is an ethi-
cally complicated study, as it would deprive 
some patients of benefit from a standard of 
care treatment. An alternative would be to mea-
sure response rates in patients treated with 
bevacizumab and to determine whether they 
were greater in patients with high plasma VEGF-
Axxxb than in those with low VEGF-Axxxb. The dis-
advantage with this process is that a very large 
number of patients would need to be entered 
into a trial to determine differences, as patients 
with high VEGF-Axxxb have a better outcome 
irrespective of bevacizumab treatment. Thus 
the “response” rates, particularly for stable dis-
ease are likely to be higher in the high VEGF-
Axxxb group irrespective of bevacizumab.
The results shown here indicate that circulating 
VEGF-Axxxb levels can be used a a surrogate of 
tumour relative VEGF-Axxxb levels, and that this 
suggests that a prospective trial of bevacizum-
ab treatment based on VEGF-Axxxb levels is war-
ranted, particularly in health care systems 
where bevacizumab is not available for meta-
static colorectal cancer, and potentially for 
other cancers too.
We are in the molecular era of chemotherapeu-
tics, with trials examining neoadjuvant chemo-
therapy and targeted receptor therapy, such as 
panitumumab in ras WT tumours in the FOxTROT 
study. If the VEGF angiogenic ratio proves to be 
a suitable biomarker of tumour response to 
bevacizumab, it begs the question of whether 
or not it will have a role in neoadjuvant 
treatment. 
This opens the possibility of a radical change in 
the way operable colorectal cancer is managed 
(with targeted receptor therapy pre-resection) 
as well as tailored adjuvant therapy or succes-
sive therapy in progressive colorectal cancer 
cases.
Acknowledgements
This work was funded by the Elizabeth Blackwell 
Institute, Cancer Research UK (A14995) 
BBSRC (BB/J007293/1) and the (MRC 
G10002073). 
Disclosure of conflict of interest
Professor Harper and Bates are co-inventors 
on a patent describing VEGF-Axxxb isoforms.
Address correspondence to: Dr. David Bates, Can- 
cer Biology, Division of Cancer and Stem Cells, 
School of Medicine, University of Nottingham, 
Queen’s Medical Centre, Nottingham NG2 7UH. 
E-mail: David.Bates@nottingham.ac.uk
References
[1] Hanahan D and Weinberg RA. The hallmarks of 
cancer. Cell 2000; 100: 57-70.
Plasma VEGF-Axxxb predicts tumour VEGF isoform ratios
2089 Am J Cancer Res 2015;5(6):2083-2089
[2] Nakayama Y, Inoue Y, Nagashima N, Katsuki T, 
Matsumoto K, Shibao K, Tsurudome K, Hirata 
K, Sako T, Nagata N and Itoh H. Relationships 
between local and systemic expression of in-
terleukin-12 and plasma levels of vascular en-
dothelial growth factor in patients with gastric 
cancer. Anticancer Res 2004; 24: 3289-3294.
[3] Giantonio BJ, Catalano PJ, Meropol NJ, O’Dwyer 
PJ, Mitchell EP, Alberts SR, Schwartz MA and 
Benson AB 3rd; Eastern Cooperative Oncology 
Group Study E3200. Bevacizumab in combina-
tion with oxaliplatin, fluorouracil, and leucovo-
rin (FOLFOX4) for previously treated metastatic 
colorectal cancer: results from the Eastern 
Cooperative Oncology Group Study E3200. J 
Clin Oncol 2007; 25: 1539-1544.
[4] Hurwitz H, Fehrenbacher L, Novotny W, 
Cartwright T, Hainsworth J, Heim W, Berlin J, 
Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe 
G, Rogers B, Ross R and Kabbinavar F. 
Bevacizumab plus irinotecan, fluorouracil, and 
leucovorin for metastatic colorectal cancer. N 
Engl J Med 2004; 350: 2335-2342.
[5] Jubb AM, Hurwitz HI, Bai W, Holmgren EB, 
Tobin P, Guerrero AS, Kabbinavar F, Holden SN, 
Novotny WF, Frantz GD, Hillan KJ and Koeppen 
H. Impact of vascular endothelial growth fac-
tor-A expression, thrombospondin-2 expres-
sion, and microvessel density on the treatment 
effect of bevacizumab in metastatic colorectal 
cancer. J Clin Oncol 2006; 24: 217-227.
[6] Bates DO, Cui TG, Doughty JM, Winkler M, 
Sugiono M, Shields JD, Peat D, Gillatt D and 
Harper SJ. VEGF165b, an inhibitory splice vari-
ant of vascular endothelial growth factor, is 
down-regulated in renal cell carcinoma. Cancer 
Res 2002; 62: 4123-4131.
[7] Qiu Y, Bevan H, Weeraperuma S, Wratting D, 
Murphy D, Neal CR, Bates DO and Harper SJ. 
Mammary alveolar development during lacta-
tion is inhibited by the endogenous antiangio-
genic growth factor isoform, VEGF165b. Faseb 
J 2008; 22: 1104-1112.
[8] Konopatskaya O, Churchill AJ, Harper SJ, Bates 
DO and Gardiner TA. VEGF165b, an endoge-
nous C-terminal splice variant of VEGF, inhibits 
retinal neovascularization in mice. Mol Vis 
2006; 12: 626-632.
[9] Hua J, Spee C, Kase S, Rennel ES, Magnussen 
AL, Qiu Y, Varey A, Dhayade S, Churchill AJ, 
Harper SJ, Bates DO and Hinton DR. 
Recombinant human VEGF165b inhibits ex-
perimental choroidal neovascularization. In- 
vest Ophthalmol Vis Sci 2010; 51: 4282-4288.
[10] Pritchard-Jones RO, Dunn DB, Qiu Y, Varey AH, 
Orlando A, Rigby H, Harper SJ and Bates DO. 
Expression of VEGF(xxx)b, the inhibitory iso-
forms of VEGF, in malignant melanoma. Br J 
Cancer 2007; 97: 223-230.
[11] Rennel E, Varey AHR, Churchill AJ, Wheatley 
ER, Stewart L, Mather S, Bates DO and Harper 
SJ. VEGF121b, a new member of the VEGFxxxb 
family of VEGF-A splice isoforms, inhibits neo-
vascularisation and tumour growth in vivo. Br J 
Cancer 2009; 101: 1250-1257.
[12] Rennel E, Waine E, Guan H, Schuler Y, Leenders 
W, Woolard J, Sugiono M, Gillatt D, Kleinerman 
E, Bates D and Harper S. The endogenous anti-
angiogenic VEGF isoform, VEGF165b inhibits 
human tumour growth in mice. Br J Cancer 
2008; 98: 1250-1257.
[13] Varey AH, Rennel ES, Qiu Y, Bevan HS, Perrin 
RM, Raffy S, Dixon AR, Paraskeva C, Zaccheo 
O, Hassan AB, Harper SJ and Bates DO. VEGF 
165 b, an antiangiogenic VEGF-A isoform, 
binds and inhibits bevacizumab treatment in 
experimental colorectal carcinoma: balance of 
pro- and antiangiogenic VEGF-A isoforms has 
implications for therapy. Br J Cancer 2008; 98: 
1366-1379.
[14] Bates DO, Catalano PJ, Symonds KE, Varey AH, 
Ramani P, O’Dwyer PJ, Giantonio BJ, Meropol 
NJ, Benson AB and Harper SJ. Association be-
tween VEGF splice isoforms and progression-
free survival in metastatic colorectal cancer 
patients treated with bevacizumab. Clin Cancer 
Res 2012; 18: 6384-6391.
[15] Woolard J, Wang WY, Bevan HS, Qiu Y, 
Morbidelli L, Pritchard-Jones RO, Cui TG, 
Sugiono M, Waine E, Perrin R, Foster R, Digby-
Bell J, Shields JD, Whittles CE, Mushens RE, 
Gillatt DA, Ziche M, Harper SJ and Bates DO. 
VEGF165b, an inhibitory vascular endothelial 
growth factor splice variant: mechanism of ac-
tion, in vivo effect on angiogenesis and endog-
enous protein expression. Cancer Res 2004; 
64: 7822-7835.
[16] Perrin RM, Konopatskaya O, Qiu Y, Harper S, 
Bates DO and Churchill AJ. Diabetic retinopa-
thy is associated with a switch in splicing from 
anti- to pro-angiogenic isoforms of vascular en-
dothelial growth factor. Diabetologia 2005; 48: 
2422-2427.
